Literature DB >> 22155911

Novel resistance-associated mutations of thymidine kinase and DNA polymerase genes of herpes simplex virus type 1 and type 2.

Andreas Sauerbrei1, Kathrin Bohn, Albert Heim, Jörg Hofmann, Benedikt Weissbrich, Paul Schnitzler, Dieter Hoffmann, Roland Zell, Gerhard Jahn, Peter Wutzler, Klaus Hamprecht.   

Abstract

BACKGROUND: Studies to verify correlations between phenotypes and genotypes of herpes simplex virus (HSV) are an important tool to establish a database of resistance-associated mutations.
METHODS: In this study, 32 acyclovir (ACV)-resistant clinical HSV-1 and 4 ACV-resistant clinical HSV-2 isolates were examined in parallel by both phenotypic and genotypic resistance testing. Additionally, five non-viable HSV-1 strains and two non-viable HSV-2 strains with clinical resistance were included in genotypic resistance analysis.
RESULTS: All ACV-resistant HSV isolates showed cross-resistance to brivudin and penciclovir, and were sensitive to foscarnet and cidofovir. Acyclovir resistance was assigned to frameshift and single non-synonymous mutations of the thymidine kinase (TK) gene in 32 out of 37 HSV-1 strains and in 4 out of 6 HSV-2 strains. In three HSV-1 isolates, there were resistance-associated amino acid substitutions of the DNA polymerase (pol). Six substitutions in the TK and two in the DNA pol gene could not be attributed without doubt to either ACV resistance or natural gene polymorphism. Altogether, 10 resistance-related mutations in the TK and 1 in the DNA pol gene have not been reported previously.
CONCLUSIONS: The novel non-synonymous mutations found in this study enrich the knowledge about the genetic alterations of TK and DNA pol genes in ACV-resistant clinical HSV strains. Together with data from the literature, the findings justify the generation of a HSV database that contains resistance mutations associated with ACV resistance phenotype.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22155911     DOI: 10.3851/IMP1870

Source DB:  PubMed          Journal:  Antivir Ther        ISSN: 1359-6535


  13 in total

1.  Acyclovir resistance in herpes simplex virus type I encephalitis: a case report.

Authors:  Andreas Sauerbrei
Journal:  J Neurovirol       Date:  2017-06-21       Impact factor: 2.643

2.  Evaluation of Unbiased Next-Generation Sequencing of RNA (RNA-seq) as a Diagnostic Method in Influenza Virus-Positive Respiratory Samples.

Authors:  Nicole Fischer; Daniela Indenbirken; Thomas Meyer; Marc Lütgehetmann; Heinrich Lellek; Michael Spohn; Martin Aepfelbacher; Malik Alawi; Adam Grundhoff
Journal:  J Clin Microbiol       Date:  2015-05-13       Impact factor: 5.948

3.  Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance.

Authors:  Susanne Schmidt; Kathrin Bohn-Wippert; Peter Schlattmann; Roland Zell; Andreas Sauerbrei
Journal:  Antimicrob Agents Chemother       Date:  2015-06-08       Impact factor: 5.191

4.  Antiviral Drugs Against Herpesviruses.

Authors:  Jocelyne Piret; Guy Boivin
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

5.  Overcoming drug-resistant herpes simplex virus (HSV) infection by a humanized antibody.

Authors:  Adalbert Krawczyk; Michaela A E Arndt; Ludger Grosse-Hovest; Wilko Weichert; Bernd Giebel; Ulf Dittmer; Hartmut Hengel; Dirk Jäger; Karl E Schneweis; Anna M Eis-Hübinger; Michael Roggendorf; Jürgen Krauss
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-08       Impact factor: 11.205

6.  The HIV Integrase Inhibitor Raltegravir Inhibits Felid Alphaherpesvirus 1 Replication by Targeting both DNA Replication and Late Gene Expression.

Authors:  Matthew R Pennington; Ian E H Voorhees; Heather M Callaway; Shannon D Dehghanpir; Joel D Baines; Colin R Parrish; Gerlinde R Van de Walle
Journal:  J Virol       Date:  2018-09-26       Impact factor: 5.103

7.  Prevalence of Intrathecal Acyclovir Resistant Virus in Herpes Simplex Encephalitis Patients.

Authors:  Johanna G Mitterreiter; Maarten J Titulaer; Gijsbert P van Nierop; Jeroen J A van Kampen; Georgina I Aron; Albert D M E Osterhaus; Georges M G M Verjans; Werner J D Ouwendijk
Journal:  PLoS One       Date:  2016-05-12       Impact factor: 3.240

8.  Study of Antiherpetic Efficiency of Phosphite of Acycloguanosine Ableto Over come the Barrier of Resistance to Acyclovir.

Authors:  V L Andronova; M V Jasko; M K Kukhanova; G A Galegov; Yr S Skoblov; S N Kochetkov
Journal:  Acta Naturae       Date:  2016 Jan-Mar       Impact factor: 1.845

9.  Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016.

Authors:  Andrew J Ullmann; Martin Schmidt-Hieber; Hartmut Bertz; Werner J Heinz; Michael Kiehl; William Krüger; Sabine Mousset; Stefan Neuburger; Silke Neumann; Olaf Penack; Gerda Silling; Jörg Janne Vehreschild; Hermann Einsele; Georg Maschmeyer
Journal:  Ann Hematol       Date:  2016-06-24       Impact factor: 3.673

10.  Recombinant herpes simplex virus type 1 strains with targeted mutations relevant for aciclovir susceptibility.

Authors:  Anne-Kathrin Brunnemann; Kristin Liermann; Stefanie Deinhardt-Emmer; Gregor Maschkowitz; Anja Pohlmann; Beate Sodeik; Helmut Fickenscher; Andreas Sauerbrei; Andi Krumbholz
Journal:  Sci Rep       Date:  2016-07-18       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.